Study On Different Dosing Regimens Of Inhaled Budesonide Suspension On Acute Exacerbations Of Copd

Objective:To investigate the clinical effects and safety of inhaling different dose of budesonide (BUD) suspension in combination with ipratropium bromide and salbutamol compound on patients with acute exacerbations of COPD (AECOPD). And to investigate the optimum dose of inhaled glucocorticoid in these patients.Methods:120 Patients with moderate to severe AECOPD were divided into three groups. Patients in control group received ipratropium bromide 500 microg and salbutamol 3 mg, q6 h, on this base, the experimental groups 1 and 2 received BUD 1 mg or 2 mg added in the nebulizer each time. All the patients were given oxygen, antibiotic drugs, aminophylline if necessary. The observation duration was 10 days.Results:The therapeutic efficiency of group 2 (92.6%) was significantly higher than those of control group (69.2%,P<0.01) and group 1 (82.5%,P<0.05). At the 5th day of treatment, the increase of FEV1 were 10.0% in control group,15.8% in group 1 and 23.7%in group 2. And at the 10th day, those were 22.8%,29.4% and 32.9%. The increase of FEV1 was much higher in group 2 than the control group (P<0.01) and group 1 (P<0.05). The alternation of FVC were in the similar tendency. Comparing with the data before treatment, SpO2was significantly increased in group 2 after 48 h-treatment and in control group and group 1 after 72 h-treatment.Conclusions:More significant and quick improvement of lung function and life quality was seen in AECOPD Satients with inhaled BUD suspension in combination with ipratropium bromide and salbutamol compound rather than those with single bronchodilators, especially in group 2. Treatment with BUD 2 mg/d q6h for 10 days was safe and no serious adverse was seen in patients.